2019³â Á¦60Â÷ ´ëÇÑÇÙÀÇÇÐȸ ÇÙÀÇÇÐ ¿¬¼ö±³À° : 2019-05-03±³À°ÀÏÀÚ : 2019-05-03
±³À°Àå¼Ò : ±×·£µå ÇöóÀÚ Ã»ÁÖÈ£ÅÚ 3Ãþ ±×·£µåº¼·ë A
±³À°ÁÖÁ¦ :
2019³â Á¦60Â÷ ´ëÇÑÇÙÀÇÇÐȸ ÇÙÀÇÇÐ ¿¬¼ö±³À°ÁÖÃÖ±â°ü : ´ëÇÑÇÙÀÇÇÐȸ
´ã´çÀÚ : ³²Àº°æ
¿¬¶ôó : 02-745-2040
À̸ÞÀÏ :
ksnm@ksnm.or.kr ±³À°Á¾·ù : ÇÙÀÇÇаú
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª :
ÃæûºÏµµ±³À°½Ã°£ : 3 ½Ã°£ 30ºÐ
¼¼ºÎ¼ö°·á : 35,000¿ø
ºñ°í Á¤È¸¿ø: 35,000 / ÁØȸ¿ø: 35,000 / ¼ö·Ãȸ¿ø: 25,000 ºñȸ¿ø: 55,000
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 05-03 ±×·£µå ÇöóÀÚ Ã»ÁÖÈ£ÅÚ 3Ãþ ±×·£µåº¼·ë A 14:30~14:55 Use of F-18 FDOPA PET for neuroendocrine tumors ±è¿ëÀÏ(¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 05-03 ±×·£µå ÇöóÀÚ Ã»ÁÖÈ£ÅÚ 3Ãþ ±×·£µåº¼·ë A 14:55~15:20 Use of Ga-68 DOTATOC for neuroendocrine tumors º¯º´Çö(Çѱ¹¿øÀÚ·ÂÀÇÇпø)
±³À°½Ã°£ 05-03 ±×·£µå ÇöóÀÚ Ã»ÁÖÈ£ÅÚ 3Ãþ ±×·£µåº¼·ë A 15:20~15:45 Use of PSMA PET in prostate cancer patients Á¶¿µ¼®(»ï¼º¼¿ïº´¿ø)
ÈÞ½Ä 05-03 ±×·£µå ÇöóÀÚ Ã»ÁÖÈ£ÅÚ 3Ãþ ±×·£µåº¼·ë A 15:45~16:00 Coffee break Coffee break(Coffee break)
±³À°½Ã°£ 05-03 ±×·£µå ÇöóÀÚ Ã»ÁÖÈ£ÅÚ 3Ãþ ±×·£µåº¼·ë A 16:00~16:25 Use of F-18 choline PET for prostate cancer ÇϽ±Õ(¼¿ï´ëº´¿ø)
±³À°½Ã°£ 05-03 ±×·£µå ÇöóÀÚ Ã»ÁÖÈ£ÅÚ 3Ãþ ±×·£µåº¼·ë A 16:25~16:50 Use of F-18 FET for brain tumor ÀÌ¿ø¿ì(ºÐ´ç¼¿ï´ëº´¿ø)
±³À°½Ã°£ 05-03 ±×·£µå ÇöóÀÚ Ã»ÁÖÈ£ÅÚ 3Ãþ ±×·£µåº¼·ë A 16:50~17:15 Use of F-18 NaF in cardiovascular disease ä¼±¿µ(¼¿ï¾Æ»êº´¿ø)
Åä·Ð 05-03 ±×·£µå ÇöóÀÚ Ã»ÁÖÈ£ÅÚ 3Ãþ ±×·£µåº¼·ë A 17:30~18:30 Àü°øÀÇ ±³À°¼ö·Ã ȯ°æ°³¼± Åä·Ðȸ °¿øÁØ(½ÅÃ̼¼ºê¶õ½º)